Title
Use of angioembolization in urology: a review.

Permalink
https://escholarship.org/uc/item/1255g98k

Journal
Translational andrology and urology, 7(4)

ISSN
2223-4691

Authors
Fergus, KB
Baradaran, N
Tresh, A
et al.

Publication Date
2018-08-01

DOI
10.21037/tau.2018.05.12

Peer reviewed
Use of angioembolization in urology: a review

Kirkpatrick B. Fergus¹, Nima Baradaran¹, Anas Tresh¹, Miles B. Conrad², Benjamin N. Breyer¹³

¹Department of Urology, ²Department of Radiology and Biomedical Imaging, ³Department of Biostatistics and Epidemiology, University of California-San Francisco, San Francisco, CA, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study material or patients: None; (IV) Collection and assembly of data: KB Fergus; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Benjamin N. Breyer, MD, MAS, FACS. Associate Professor of Urology, University of California-San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero Suite 3A, San Francisco, CA 94110, USA. Email: Benjamin.Breyer@ucsf.edu.

Abstract: This review discusses current and developing indications for angioembolization (AE) techniques in urology cases, including trauma and non-trauma uses for kidney, prostate, and bladder conditions. AE methods, complications and technical and clinical outcomes are outlined for each indication for the purpose of aiding urologists in selecting ideal candidates for this procedure.

Keywords: Angioembolization (AE); benign prostatic hyperplasia (BPH); embolization; trauma

Submitted Mar 11, 2018. Accepted for publication May 14, 2018.
doi: 10.21037/tau.2018.05.12
View this article at: http://dx.doi.org/10.21037/tau.2018.05.12

Introduction: role of angioembolization (AE) in urology

AE is a minimally invasive procedure in which interventional radiologists access peripheral arteries under image guidance to selectively occlude the blood supply of target tissues. It has become an increasingly important tool in the arsenal of treatments for urological conditions since its origin in the 1970's. The role of AE is established in the treatment of hemorrhagic emergencies in urology and recently it has been investigated in other pathologies such as in BPH and prostate cancer. Urologists should be familiar with AE and its clinical indications, as well as its risks, benefits, and alternatives. This critical review aims to present the current state of AE techniques used in urological cases for the benefit of the practicing urologist.

AE methods

Access for renal artery embolization, one of the more established urologic indications, is typically gained through the common femoral artery, or left radial artery. The brachial or axillary arteries can be used as back-up options (1). Ultrasound is often used to puncture the artery with a needle allowing advancement of a guide wire and sheath. A 5 French catheter is then advanced into the target organ artery (e.g., renal) and through this, a microcatheter and wire are used to select distal branches. Embolic agents are loaded into the catheter and injected or pushed into the target artery. Embolization agents can be categorized as coils, plugs and particles and either temporary or permanent. Modern coils and plugs are made of MRI compatible metal alloys such as nitinol. Particles, can be selected based on their size range (e.g., 300–500 μm), shape, and pliability. The most commonly used temporary embolic agent is gelfoam which can be molded into injectable torpedo like pledgets or agitated to create a particle slurry. A summary of typical embolic agents used in a given procedure can be found in Figure 1.

AE in renal trauma

In broad terms, non-invasive strategies are preferred in hemodynamically stable renal trauma patients. Surgical interventions as well as AE are reserved for cases of persistent bleeding (6,7). Breyer et al. previously discussed a treatment algorithm for management of renal trauma (Figure 2), which complements current American Urological
Association (AUA) Guidelines (6,7). The first step is intravenous contrast-enhanced CT imaging with delayed and immediate phases for diagnostic purposes, which provides the renal trauma grade and a visual of the renal arteries, veins, and parenchyma. Management strategies are contingent on the trauma grade, the integrity of renal vascular structures, and the hemodynamic stability of the patient. Hemodynamically stable patients are managed with non-invasive strategies including observation, rest and serial hematocrit measurements according to Breyer et al. and AUA Guidelines (grade B evidence strength) (6,7). On the other hand, patients with persistent bleeding may ultimately require intervention. Further, hemodynamically unstable patients that do not respond—or transiently

---

Figure 1 Common embolic agents in angioembolization procedures (1-5). For each of the urologic indications for angioembolization, common embolic agents are listed, though the list is not exhaustive.

---

Figure 2 Minimally invasive techniques for acute renal hemorrhage. This is a management algorithm for renal trauma produced by Breyer et al. 2008. Reproduced with permission from Dr. Benjamin Breyer and Elsevier Publishing Company.
respond—to resuscitation require immediate intervention (Grade B evidence strength) (6). According to Breyer et al., indications for surgery over AE techniques in hemodynamically unstable patients include grade V renal injury, avulsion of the renal pelvis, and damage to the main renal artery and vein (though renal artery stent is another option for this indication) (7).

Primary AE interventions are ideally suited for patients with persistent bleeding, lower than grade V injury, and an intact main renal artery and vein (7). Studies of AE techniques in this patient population found final technical and clinical success rates above 90% (7-9). For patients with grade V renal injury, two large studies found mixed evidence of success (7,9). It is reasonable to anticipate subsequent interventions when using AE to treat grade V renal injuries, and as such it is currently not recommended as first-line treatment, especially in context of currently available surgical interventions (7).

All cases of conservatively managed renal trauma should be monitored and observed for a change in hemodynamic status, as delayed hemorrhage such as from a pseudoaneurysm is possible (10,11). As one prospective study found, 18% of those treated with non-operative intent ultimately needed surgical intervention (12). In these cases of delayed hemorrhage, AE is a good first-line choice of treatment.

Iatrogenic injuries

AE techniques are also used successfully in the case of iatrogenic vascular injury of the kidney to cease or abate resultant bleeding (13). Iatrogenic vascular injuries consist of intraparenchymal pseudoaneuysms, intraoperative/post-operative hemorrhage, or arteriovenous (AV) fistulas. Pseudoaneuysms are arterial perforations that are contained by parenchyma or adventitia and are prone to rupture. AV fistulas are connections between arteries and veins (14). Frequently AV fistula is seen in the presence of a pseudoaneuysm (Figure 3). Pseudoaneuysms and AV fistulas can decompress into the collecting system causing hematuria. Iatrogenic causes of these phenomena can be related to surgeries or procedures, including partial nephrectomy, renal biopsy, guidewire arterial perforation in angiography or renal stenting, or percutaneous nephrolithotomy (13).

Complications due to partial nephrectomy are among the most common iatrogenic renal vascular injuries for which AE is indicated. A large, multi-center retrospective study of 998 minimally invasive partial nephrectomy procedures found that approximately 2% resulted in iatrogenic vascular injury (15). A study of 1,425 patients in Germany undergoing partial nephrectomy found similar results, with 2.7% resulting in pseudoaneurysm or arteriovenous fistula (16). Pseudoaneuysms, though rare, usually present around 14.9 days after surgery (17). Patients with pseudoaneuysms experience gross hematuria and flank pain, and sometimes dizziness and fever. AE has been shown to be safe and effective with success rates as high as 96–100% (17-19). Although vascular injury can occur in 8% of cases after renal biopsy, as little as 1% may require intervention with selective AE, with similar findings for complications of percutaneous nephrolithotomy and guidewire perforation of the renal artery (13,20-23).

Non-trauma indications for renal AE

Angiomyolipoma (AML)

In the case of renal AMLs, both renal AE and surgical excision are efficacious treatments for patients experiencing pain or hemorrhage, particularly if symptoms are accompanying a tumor >4 cm (24,25). Other minimally invasive treatment modalities include laparoscopic/ percutaneous ablation (including radiofrequency ablation, microwave ablation, and cryoablation) as well as robot-assisted laparoscopic partial nephrectomy (26). AMLs are
relatively rare, occurring with an incidence of 0.1–0.2% (27). The current literature on the topic is thus based on relatively smaller sample sizes. In the absence of guidelines or randomized controlled trials, urologists must first consider the following: number of tumors, size and location, efficacy and risks, co-morbidities, renal function of the patient, and patient/provider preference (28). In one retrospective study from 1999–2009 in Vancouver, surgery was more common than renal AE overall (42 vs. 17 cases), though renal AE was more common in the case of multifocal AML (35% vs. 7%) and in acute hemorrhage (50% vs. 15%) (28). At our institution, AML embolization is performed with a mixture of high concentration ethanol and lipiodol. This procedure can be challenging, as one study of 17 patients with AML reported aneurysm rupture with extravasation can occur, sometimes requiring a second embolization (27). In rare cases, pregnant patients can experience growth and rupture of AMLs during pregnancy, which is hypothesized to be associated with hormone stimulation (24). Cases of managing these patients with selective AE exist, though the procedure should be used with caution (24).

Renal cancer

There is a role for renal AE in renal malignancy as an adjunct to surgery. An important advantage of occluding the blood supply to the point of infarction is reducing tumor dimension, bulk and burden prior to partial or total nephrectomy (29). It is also well-established that AE prior to surgery reduces intraoperative blood loss, and it is reported that the resultant plane of edema facilitates resection with a peak effect occurring at 72 hours (29-31). In fact, a retrospective case-control study of pre-operative AE versus surgery alone controls matched for age, sex and tumor stage, size and grade found the treatment patients had increased 5- and 10-year survival (62% and 47% respectively) when compared to no treatment (35% and 23%) (32). In the event of spontaneous uncontrolled bleeding originating in the malignant renal mass, embolization is both safe and effective. Another important use of AE is palliation for unresectable malignancy as it can minimizes tumor bulk and size and reduces hematuria and flank pain for symptomatic relief (29). However, the procedure is not without drawbacks, as many patients experience post-infarction syndrome in which fever, nausea, vomiting and pain occur 1–3 days post-procedure (33). More serious complications, though rare, include embolization of unintended vessels and tubular necrosis (33).

Arteriovenous malformation & fistula

Although arteriovenous (AV) malformations are typically due to trauma and can result from iatrogenic insults, other rare congenital forms exist such as hemangiomas. The clinical presentation of arteriovenous malformations includes flank pain, perinephric hematoma, gross hematuria, hypertension, or high output cardiac failure (34). AV malformations are difficult to definitively cure, and patients may require intermittent treatment throughout their lives (5). These cases can be technically challenging for interventional radiologists as AV malformations often have high rate of blood flow. However, embolization techniques have been shown to be safe and effective in treating AV malformations, including those of congenital origin (35-37). Technical and clinical success rates vary from 67–87% (35,38). Smaller studies report higher technical and clinical success rates (36,39). Specifically for renal arteriovenous fistulas, embolization intervention is lasting, with one study showing a cease of symptoms over a 10-year study period (40).

Parenchymal disease: polycystic kidney disease & end-stage renal disease

Reports of renal parenchymal indications are predominantly outside of the United States. In patients with severe flank pain in the context of end-stage renal disease (ESRD), embolization has been proposed as an alternative to nephrectomy (41). It has also been proposed to reduce kidney size and make transplantation more feasible. Cyst diameter expansion in ADPKD is linked to increased vascular supply via angiogenesis, which is one of the reasons why embolization has been successful in renal volume reduction in numerous observational studies (41). For patients with ESRD, complete occlusion of renal artery starting with the peripheral vessels and moving to larger vessels has been shown in small-sample studies to be a safe and effective alternative to nephrectomy (5,42-44).

Non-renal urology indications for AE

Benign prostatic hyperplasia (BPH)

Since the initial case reports of treating BPH with prostate artery embolization (PAE) in 2010 (45), several studies have found it to be safe and efficacious (46).
procedure involves selective cannulation of the bilateral prostatic arteries and injection of microspheres into each side to achieve stasis in the prostatic arteries. To date, there are two short term prospective trials comparing PAE to transurethral resection of the prostate (TURP). These demonstrate that both procedures resulted in similar symptom improvement. A 2014 trial showed that TURP yielded greater improvement in symptoms and urodynamic parameters (47). PAE had a lower technical and clinical success rate (94.7% and 90.6% respectively) than TURP (100% and 96.1%) (47). A more recent trial using a modified embolization technique demonstrated similar symptomatic improvement between both groups but the TURP group demonstrated better urodynamic improvement and more adverse sequelae than the PAE group (48).

There is no long term clinical trial comparing PAE and TURP. One prospective cohort study of 630 patients receiving PAE for BPH found 76.3% had clinical success over medium term follow-up (>3–6.5 years), with none of their patients reporting urinary incontinence or sexual dysfunction (49). At 36 months in this study, mean improvement in IPSS was 12.1 points (SD =8.6) and mean Qmax improvement was 3.21 mL/min (SD =10.3) (49). Moreover, the vast majority of studies report prostatic AE has no adverse effect on erectile function (50). Major complications do occur in rare cases, including retropubic, urethral, or perineal pain, hematuria, and intraluminal necrotic prostate tissue (51,52). Numerous small-sample, single-arm trials have demonstrated safety and short-term clinical success of prostatic AE in the treatment of BPH (53-57). A few studies have found initial efficacy in treating large-prostate BPH, defined as >90 g or >80 mL (56,58-60). Candidates for prostatic AE typically have isolated BPH without underlying malignancy, coagulopathy, atherosclerosis, or dysfunction of the bladder, urethra, sphincters, or the innervation of these structures (2,61).

Bladder & prostate hemorrhage

Selective arterial embolization controls life-threatening bleeding in the case of persistent hematuria or frank hemorrhage of the bladder or prostate. It is considered to be a minimally invasive alternative to surgery when conservative management fails (4). Delgal et al. conducted a retrospective cohort study of 20 patients with bladder and/or prostate hemorrhage that received AE treatments and found a technical success rate of 90% (62). AE has also been used successfully in the treatment of hemorrhagic cystitis, including after hematopoietic stem cell transplantation (63,64). These techniques are also used in the treatment of bleeding secondary to radical prostatectomy (65). In the rare condition of arterial-ureteral fistulas with failed endovascular stenting, case reports of successful ureteral stump coil AE methods exist though efficacy has not been demonstrated (66,67).

High flow priapism

Although conservative management is first-line, a series of cases using AE techniques to manage high flow priapism exists in the literature. Temporary occlusive agents are preferred to preserve erectile function, with some physicians reporting the use of autologous blood clots (68). In a multi-center study of 27 patients receiving embolization for high flow priapism, the procedure achieved 89% durable clinical success on the first attempt (68). Reduced sexual function is the primary adverse effect of interest, with small sample observational studies reporting 19–20% had reduced erection quality after the procedure (68,69). Preliminary estimates of recurrence rates are between 30–40% (70,71).

Outcomes

Technical and clinical success rates vary by procedure, and are summarized in Table 1. Post-infarction syndrome (flank pain, nausea and vomiting) is common but resolves within days, and major complications are rare. Minor complications include fever and leukocytosis and are self-limited (75).

Contrast-induced acute kidney injury (AKI) is a possible risk in all patient populations. Though this iatrogenic cause of AKI may occur in as much as 5% of patients with normal renal function, it is more common among those with reduced renal function or diabetic nephropathy (76). Methods to reduce the risk of this condition include sparing use of contrast-requiring procedures, thorough renal function assessment, adequate hydration with isotonic solution, and pharmacologic prevention strategies such as acetylcysteine and fenoldopam (77-79).

Cost

An important consideration in the age of “high value care” is the absolute cost of AE. Few studies have reported the cost of AE in the context of urological cases. However, one
Table 1 Studies of angioembolization techniques used in non-malignant urologic cases, N≥50

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Year</th>
<th>N</th>
<th>Indication</th>
<th>Technical success (first attempt)</th>
<th>Clinical success (overall, latest)</th>
<th>Define clinical success</th>
<th>Post-infarction syndrome</th>
<th>Major complication</th>
<th>Define major complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breyer et al. (7) 2008 26 Acute renal hemorrhage</td>
<td>22 (85%)</td>
<td>17 (66%)</td>
<td>Cessation of hematuria &amp; no successive embolization</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohsen et al. (8) 2008 81 Traumatic renal vascular injuries</td>
<td>–</td>
<td>79 (97.5%)</td>
<td>Cessation of hematuria immediately after procedure</td>
<td>–</td>
<td>1 (1%)</td>
<td>Perinephric abscess</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotaling et al. (9) 2011 77 Renal trauma</td>
<td>9 (12%)</td>
<td>–</td>
<td>No successive therapy</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sam et al. (72) 2011 50 Iatrogenic renal vascular injuries</td>
<td>49 (98%)</td>
<td>46 (96%)</td>
<td>Absence of clinical or imaging evidence of bleeding after procedure</td>
<td>–</td>
<td>0 (0%)†</td>
<td>SIR-criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zeng et al. (23) 2013 117 Iatrogenic vascular injuries</td>
<td>105 (90%)</td>
<td>116 (99%)</td>
<td>Complete bleeding cessation after procedure</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pettipierre et al. (73) 2015 73 ADPKD</td>
<td>92.1%</td>
<td>89.5%</td>
<td>Withdrawal of temporary contraindication of kidney for transplant at any time point in study period</td>
<td>18.3%</td>
<td>4.1%</td>
<td>SIR-criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilhim et al. (74) 2013 103 BPH</td>
<td>–</td>
<td>72.1%</td>
<td>Persisting LUTS 1–12 months</td>
<td>–</td>
<td>2 (1.6%)</td>
<td>SIR-criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pisco et al. (52) 2013 255 BPH</td>
<td>250 (98%)</td>
<td>72%</td>
<td>Improved symptoms &amp; quality of life at 36 months</td>
<td>–</td>
<td>1 (&lt;1%)</td>
<td>Bladder ischemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gao et al. (47) 2014 57 BPH</td>
<td>54 (94.7%)</td>
<td>90.6%</td>
<td>Persisting severe symptoms and/or peak urinary flow &lt;7 mL/sec or lower after the procedure</td>
<td>6 (11.1%)</td>
<td>8 (14%)</td>
<td>Clavien III &amp; IV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang et al. (59) 2015 117 BPH, prostate &gt;80 mL</td>
<td>109 (93.2%)</td>
<td>91.7%</td>
<td>IPSS &lt;20, QoL&lt;4, Qmax improvement ≥3 at 2 years</td>
<td>–</td>
<td>0 (0%)</td>
<td>SIR-criteria; prolonged hospitalization, readmission, surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pisco et al. (49) 2016 630 BPH</td>
<td>618 (98.1%)</td>
<td>76.3%</td>
<td>QoL and IPSS score improvement at 3–6.5 years</td>
<td>–</td>
<td>1 (0.2%)</td>
<td>SIR-criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†, one patient had embolization of ureteral artery, one patient died. ADPKD, autosomal dominant polycystic kidney disease; BPH, benign prostatic hyperplasia; Clavien, Clavien-Dindo score; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; QoL, quality of life; SIR, Society for Interventional Radiology.
A large, multi-center retrospective study found the total cost of uterine artery embolization in the treatment of fibroids was lower when compared to hysterectomy (80). According to a recent study, prostatic arterial embolization costs $1,667.10 on average, which the authors compared to the $2,153.64 cost of TURP (81). On the other hand, a study of non-surgical management of blunt splenic injury found the total hospital cost of embolization to be similar to that of surgery (82). More research is necessary to determine the procedural costs, total hospital costs, and cost-effectiveness of AE used in urological cases.

Conclusions
AE techniques can be employed in a variety of urologic cases, with a series of potential new indications currently under investigation. Although AE is well established in treating renal indications, more evidence is needed to explore the safety and efficacy of other applications such as treating BPH. Though reports of technical and clinical success rates vary across the literature, the majority of procedures across indications are successful with only minor complications. However, the clinical context for these various indications is important, and Urologists are well suited to make first-line management decisions regarding patient selection for AE procedures. Urologists will thus benefit from knowing the reported outcomes for each of these procedures as it will facilitate more informed discussions with their patients when deciding on a referral. More research is needed to explore the overlap between AE and more traditional urology surgical interventions.

Acknowledgements
Funding: This work was supported by the National Center for Advancing Translational Sciences, National Institutes of Health [UCSF-CTSI Grant Number TL1 TR001871 to KB Fergus]. The project was also supported by Anita and Kevan Del Grande and Russell and Sara Hirsch.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

Disclaimer: The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

References


Fergus et al. Use of angioembolization in urology: a review

Cite this article as: Fergus KB, Baradaran N, Tresh A, Conrad MB, Breyer BN. Use of angioembolization in urology: a review. Transl Androl Urol 2018;7(4):535-544. doi: 10.21037/tau.2018.05.12
